An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup

Blood

Volumn 125, Issue 6, 2015, Pages 959-966

  Chan, Fong Chun ^a,b   Telenius, Adele ^a   Healy, Shannon ^a   Ben Neriah, Susana ^a   Mottok, Anja ^a   Lim, Raymond ^a   Drake, Marie ^a   Hu, Sandy ^a   Ding, Jiarui ^a   Ha, Gavin ^a,b   Scott, David W ^a   Kridel, Robert ^a   Bashashati, Ali ^a   Rogic, Sanja ^a   Johnson, Nathalie ^c   Morin, Ryan D ^a,d   Rimsza, Lisa M ^e   Sehn, Laurie ^a   Connors, Joseph M ^a   Marra, Marco A ^a,b   Gascoyne, Randy D ^a   Shah, Sohrab P ^a   Steidl, Christian ^a   more..

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d SIMON FRASER UNIVERSITY   (Canada)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; COREPRESSOR PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DOXORUBICIN; HISTONE DEACETYLASE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA PRECURSOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PREDNISOLONE; PROTEIN P53; RCOR 1 PROTEIN; RITUXIMAB; TRANSCRIPTOME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NERVE PROTEIN; PREDNISONE; RCOR1 PROTEIN, HUMAN;

ADULT; ANTIGEN PRESENTATION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; COPY NUMBER VARIATION; DOWN REGULATION; DRUG TREATMENT FAILURE; FEMALE; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE LOCATION; GENE LOCUS; GENE LOSS; GENE SILENCING; GENOTYPE; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LOW RISK POPULATION; LYMPHOMA CELL LINE; MALE; OVERALL SURVIVAL; OVERLAPPING GENE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RNA SEQUENCE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TRANSCRIPTION REGULATION; UPREGULATION; AGED; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PROGNOSIS; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CO-REPRESSOR PROTEINS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PREDNISONE; PROGNOSIS; TRANSCRIPTOME; VINCRISTINE;

EID: 84922346567     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-507152     Document Type: Article

References (37)

1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769): 503-511.
2. Bea S, Zettl A, Wright G, et al.; Lymphoma/Leukemia Molecular Profiling Project. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005; 106(9): 3183-3190.
3. Tagawa H, Suguro M, Tsuzuki S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood. 2005; 106(5): 1770-1777.
4. Jardin F, Jais J-P, Molina T-J, et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood. 2010; 116(7): 1092-1104.
5. Rosenwald A, Wright G, Chan WC, et al.; Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25): 1937-1947.
6. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011; 476(7360): 298-303.
7. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011; 43(9): 830-837.
8. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012; 109(10): 3879-3884.
9. Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013; 110(4): 1398-1403.
10. Friedberg JW Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011; 2011: 498-505.
11. Bashashati A, Haffari G, Ding J, et al. DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. Genome Biol. 2012; 13(12): R124.
12. Chen W, Houldsworth J, Olshen AB, et al. Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood. 2006; 107(6): 2477-2485.
13. Lenz G, Wright GW, Emre NCT, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008; 105(36): 13520-13525.
14. Kreisel F, Kulkarni S, Kerns RT, et al. High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy. Cancer Genet. 2011; 204(3): 129-137.
15. Monti S, Chapuy B, Takeyama K, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012; 22(3): 359-372.
16. Lenz G, Wright G, Dave SS, et al.; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22): 2313-2323.
17. Wang K, Li M, Hadley D, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 2007; 17(11): 1665-1674.
18. Yau C, Mouradov D, Jorissen RN, et al. A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol. 2010; 11(9): R92.
19. Beroukhim R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA. 2007; 104(50): 20007-20012.
20. Paternoster SF, Brockman SR, McClure RF, Remstein ED, Kurtin PJ, Dewald GW. A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization. Am J Pathol. 2002; 160(6): 1967-1972.
21. Wu TD, Nacu S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics. 2010; 26(7): 873-881.
22. Wu G, Feng X, Stein L. A human functional protein interaction network and its application to cancer data analysis. Genome Biol. 2010; 11(5): R53.
23. Kameoka Y, Tagawa H, Tsuzuki S, et al. Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma. Oncogene. 2004; 23(56): 9148-9154.
24. Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006; 203(2): 311-317.
25. Rui L, Emre NCT, Kruhlak MJ, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010; 18(6): 590-605.
26. Scuoppo C, Miething C, Lindqvist L, et al. A tumour suppressor network relying on the polyamine-hypusine axis. Nature. 2012; 487(7406): 244-248.
27. Curtis C, Shah SP, Chin SF, et al.; METABRIC Group. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486(7403): 346-352.
28. Liao G, Zhang M, Harhaj EW, Sun S-C. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem. 2004; 279(25): 26243-26250.
29. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007; 12(2): 131-144.
30. Nagel S, Venturini L, Przybylski GK, et al. NK-like homeodomain proteins activate NOTCH3-signaling in leukemic T-cells. BMC Cancer. 2009; 9: 371.
31. Braggio E, Keats JJ, Leleu X, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 2009; 69(8): 3579-3588.
32. Chong JA, Tapia-Ramírez J, Kim S, et al. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell. 1995; 80(6): 949-957.
33. Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science. 1995; 267(5202): 1360-1363.
34. Ballas N, Battaglioli E, Atouf F, et al. Regulation of neuronal traits by a novel transcriptional complex. Neuron. 2001; 31(3): 353-365.
35. You A, Tong JK, Grozinger CM, Schreiber SL. CoREST is an integral component of the CoREST-human histone deacetylase complex. Proc Natl Acad Sci USA. 2001; 98(4): 1454-1458.
36. Hakimi M-A, Bochar DA, Chenoweth J, Lane WS, Mandel G, Shiekhattar R. A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc Natl Acad Sci USA. 2002; 99(11): 7420-7425.
37. Huang Y, Myers SJ, Dingledine R. Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. Nat Neurosci. 1999; 2(10): 867-872.